Iso-Eremphat

Iso-Eremphat: a combined anti-tuberculosis drug

Iso-Eremphat is a combined anti-tuberculosis drug produced in Germany by Fatol Artsneimittel GmbH. It consists of two active ingredients, isoniazid and rifampicin, and is used to treat tuberculosis.

The dosage form of Iso-Eremphat is presented in the form of film-coated tablets with two dosages: 100 mg/150 mg and 150 mg/300 mg. They contain 100 mg or 150 mg of isoniazid and 150 mg or 300 mg of rifampicin, respectively.

Iso-Eremphat is used to treat tuberculosis, but also has a number of contraindications. The drug is not recommended for use in acute liver diseases, jaundice and during lactation. In addition, before using Iso-Eremphat, you should be aware of possible side effects. These include mental disorders, seizures, sleep and memory disorders, headaches, neuritis, and sometimes damage to the optic nerve. Impaired kidney and liver function, jaundice, leukopenia, anemia and allergic reactions are also possible.

There is no reliable data yet on the interaction of Izo-Eremphat with other drugs, however, during the treatment process it is necessary to establish constant monitoring of the functions of the liver, kidneys and visual organs.

The drug is prescribed with caution to patients with kidney disease and during pregnancy. Moreover, during treatment it is necessary to establish constant monitoring of the functions of the liver, kidneys and organs of vision.

Thus, Iso-Eremphat is an effective combined anti-tuberculosis drug that should be taken only as prescribed by a doctor and with strict adherence to the dosage and recommendations for use. If side effects occur, you should consult your doctor immediately.